Investment Tempus Announces $200 Million Series G-2 Financing AIT News Desk Dec 12, 2020 Tempus, a leader in artificial intelligence and precision medicine, announced an additional $200 million financing at a post-money valuation of $8.1…
Life Sciences Novellus and Tempus Announce Collaboration to Accelerate Clinical Trial Patient Enrollment AIT News Desk Nov 24, 2020 Novellus, a clinical-stage biotechnology company focused on precision oncology, and Tempus, a leader in artificial intelligence and precision…
Life Sciences Tempus Announces Strategic Collaboration With Janssen Applying Data Science to Enhance Therapeutic… AIT News Desk Nov 3, 2020 Tempus, a leader in artificial intelligence (AI) and precision medicine, announced a strategic collaboration with Janssen Research & Development,…
Life Sciences Tempus Launches COVID-19-Specific Clinical and Research Initiatives for Oncology AIT News Desk Jun 1, 2020 Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, introduced a…
Life Sciences Tempus Launches New Precision Medicine-Driven Tests: Tempus|HRD and Tempus|TO AIT News Desk Jun 1, 2020 Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, announced the…
Analytics Tempus Announces $110 Million in Series E Financing AIT News Desk Sep 12, 2018 Tempus, a leading technology company advancing precision medicine through the collection and analysis of molecular and clinical data, announced today…